Rock Health Investment in Ours Privacy — Healthcare CDP HIPAA Compliance (2025)
Rock Health's investor perspective on Ours Privacy and the healthcare marketing data compliance problem.
Key facts (2026-05-07, via search):
- Source type: Healthcare-focused digital health VC investment announcement — provides independent but financially interested assessment.
- Investment thesis (from search snippet): Rock Health invested in Ours Privacy to enable HIPAA-safe performance marketing and analytics — addressing the gap where healthcare organizations cannot safely use standard marketing CDPs due to PHI handling requirements.
- Ours Privacy differentiation (as understood by Rock Health): Prevents PHI from reaching non-compliant third-party tools while enabling HIPAA-compliant ad targeting, analytics, and audience building.
Additional product context (from PRWeb press releases, search-confirmed):
- December 2025: Launched advanced analytics suite — multi-touch attribution (MTA), web analytics, session replay, user funnels; all HIPAA-compliant.
- March 31, 2026: Launched A/B testing and personalization for healthcare marketers.
- Integration: Partners with Healthie (clinical platform); enabling HIPAA-compliant CDP workflows for healthcare SaaS builders.
- Trajectory: What began as a pixel replacement has evolved into a full-stack healthcare marketing platform (consent management, audience building, session replay, analytics, A/B testing, personalization).
KG impact:
- Raises confidence for vendor.ours-privacy candidate from 0.60 → 0.72.
- Rock Health investment is the first independent (non-vendor) source found for Ours Privacy in three runs.
- Does not yet meet the ≥0.80 threshold for auto-apply — Technical Reviewer should confirm with one additional independent source.
- Addresses queue topic "Ours Privacy HIPAA CDP independent review" (added 2026-05-06).